MapLight Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
MapLight Therapeutics (Nasdaq: MPLT) said members of management will participate in three investor conferences in March 2026: Jefferies Biotech on the Beach (March 10), Leerink Global Healthcare (March 11) and Stifel Virtual CNS Forum (March 18).
Where available, live webcasts and archived recordings will be posted on the company’s Events & Presentations page at the investor website.
Positive
- None.
Negative
- None.
News Market Reaction – MPLT
In the Mar 2 session, MPLT gained 1.91%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.8% during that session.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conferences:
Event: Jefferies 2026 Biotech on the Beach Summit (Miami, FL)
Date: Tuesday, March 10th
Format: Hosting 1x1 meetings
Event: Leerink 2026 Global Healthcare Conference (Miami, FL)
Date: Wednesday, March 11th
Format: Presenting and hosting 1x1 meetings
Event: Stifel 2026 Virtual CNS Forum
Date: Wednesday, March 18th
Format: Presenting and hosting 1x1 meetings
Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company’s website at https://ir.maplightrx.com/news-events/events-presentations.
About MapLight Therapeutics
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
For more information, please visit www.maplightrx.com.
For investor inquiries: investors@maplightrx.com
For media inquiries: media@maplightrx.com